Bristol Myers Squibb opens the week with strategy focus, shares trade on NYSE
22.06.2026 - 15:25:12 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-22, 15:22.
Bristol Myers Squibb (US0897961004) begins the week with investors assessing its long-term positioning in the U.S. large-cap pharmaceutical space alongside peers such as Pfizer and Merck on the NYSE. The focus remains on how the group aims to sustain growth with its late-stage pipeline and recent acquisitions, according to current analyst discussions from MarketScreener and Simply Wall St. Simply Wall St stock analysis
What current analyses highlight
Recent equity research summaries compiled by MarketScreener show a mixed but broadly constructive stance on Bristol Myers Squibb, with a majority of analysts keeping Buy or Outperform ratings while some houses stay Neutral as they watch patent expiries and pipeline execution. MarketScreener consensus overview
Simply Wall St notes that Bristol Myers Squibb’s valuation metrics, including price-to-earnings and cash flow generation, reflect market expectations for moderate growth balanced against the impact of loss-of-exclusivity on key legacy products, based on its June 2026 fundamental analysis update. Simply Wall St fundamental snapshot
Strategy, peers and long-term focus
In the U.S. large-cap pharmaceutical sector, Bristol Myers Squibb competes with companies such as Merck and Pfizer, which also rely heavily on oncology, immunology and cardiovascular therapies for long-term growth, as highlighted in various sector overviews from Reuters and other financial media. Reuters sector comparison
Analyst discussions emphasize the importance of Bristol Myers Squibb’s diversification across therapeutic areas and its active business development, which includes deals aimed at bolstering its pipeline in oncology, hematology and immunology to offset revenue pressure from older blockbusters, according to current consensus summaries.
Background and price data on Bristol Myers Squibb
Further figures, historical prices and company reports on the Bristol Myers Squibb shares can be found in the ad-hoc-news topic overview and the company’s Investor Relations section.
How Bristol Myers Squibb makes its money
Bristol Myers Squibb generates most of its revenue from branded prescription medicines in oncology, hematology, immunology and cardiovascular disease, including well-known products such as Eliquis for stroke prevention and Opdivo for various cancer indications, as described in its company profile and latest annual report.
Where the shares trade today
The Bristol Myers Squibb shares (US0897961004) trade on the NYSE in U.S. dollars; the latest available closing price from mid-June 2026 shows the stock around the mid-50s USD range on common market data platforms.
Key data on the Bristol Myers Squibb shares
- Company: Bristol-Myers Squibb Company
- ISIN: US0897961004
- WKN: 850501
- Ticker: BMY
- Trading venue: NYSE
- Price (as of 2026-06-18, 15:59): 54.10 USD
- Market cap: 110,000,000,000 USD (as of 2026-06-18)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on publicly available sources believed to be reliable but are not guaranteed. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor.
